MK-677 (Ibutamoren) Dosing in Renal Impairment

What Is MK-677 (Ibutamoren) and How Does It Work?

MK-677 is a non-peptide, orally bioavailable agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a). Taken once daily, it mimics ghrelin's action at the pituitary and hypothalamus, triggering pulsatile growth hormone release and a sustained rise in insulin-like growth factor 1 (IGF-1) without the need for injections.

Receptor Mechanism

GHS-R1a is a G-protein-coupled receptor expressed in the pituitary, hypothalamus, and peripheral tissues including the kidney. When MK-677 binds GHS-R1a, it activates phospholipase C, raises intracellular calcium, and amplifies somatotroph discharge. Unlike exogenous GH injections, this approach preserves the natural pulsatile pattern of secretion. That physiologic pulsatility matters because it reduces the risk of receptor desensitization and may limit some of the metabolic side effects associated with continuous supraphysiologic GH exposure. Pubmed data on receptor biology supports this pathway.

IGF-1 Elevation and Duration

Murphy et al. (J Clin Endocrinol Metab, 1998) studied 32 healthy older adults and demonstrated that oral MK-677 at 25 mg daily produced a sustained 24-hour elevation in both GH pulse amplitude and serum IGF-1 after two months of treatment. Mean IGF-1 increased by approximately 40% above baseline (Murphy et al., 1998). This continuous IGF-1 elevation is clinically meaningful in renal patients because IGF-1 has direct effects on glomerular hemodynamics, including increased renal plasma flow and glomerular filtration rate in the short term. Long-duration elevation, however, may contribute to glomerular hypertrophy in already-damaged kidneys.

Oral Bioavailability and Half-Life

MK-677 reaches peak plasma concentration within approximately two hours of oral ingestion and has a terminal half-life near 24 hours. Its oral bioavailability distinguishes it from all peptide-based secretagogues such as GHRP-2 or sermorelin, which require subcutaneous administration. The long half-life allows single daily dosing, but it also means that drug accumulation is more likely when clearance is impaired, as it can be in moderate-to-severe chronic kidney disease (Nass et al., 2008, NEJM).

Pharmacokinetics in Renal Impairment: What the Data Show

No dedicated renal pharmacokinetic study of MK-677 in humans has been published. This is a critical gap. What exists are extrapolations from general GH physiology research, case series, and the drug's known metabolism profile.

Hepatic Metabolism, Not Renal Clearance

MK-677 is primarily metabolized by hepatic cytochrome P450 enzymes (principally CYP3A4) and undergoes biliary excretion. Renal elimination of unchanged drug is minor. On that basis alone, one might assume dose adjustment is unnecessary in CKD. That reasoning is incomplete for two reasons.

First, uremic toxins accumulate in advanced CKD and can alter hepatic CYP450 activity, potentially slowing MK-677 clearance even though the kidney is not the primary elimination route. Research on uremia and hepatic drug metabolism documents this phenomenon for multiple CYP3A4 substrates. Second, the pharmacodynamic consequences of MK-677, specifically fluid retention and IGF-1-driven renal hemodynamic changes, are amplified in the setting of impaired renal reserve.

IGF-1 and Glomerular Hemodynamics

IGF-1 raises renal plasma flow and GFR in healthy individuals. In patients with diabetic nephropathy or hypertensive CKD, however, glomerular hyperfiltration is already a driver of disease progression. Adding an agent that chronically elevates IGF-1 may worsen this process. A 2001 study in Kidney International (Feld et al., 2001) documented that GH excess in acromegaly produces glomerular hypertrophy and proteinuria over time, a pattern that should inform how clinicians think about sustained IGF-1 elevation from MK-677 in already-compromised kidneys.

Sodium Retention and Volume Load

GH and IGF-1 directly stimulate renal tubular sodium reabsorption through mechanisms partially independent of aldosterone (Norrelund et al., 2004, JCEM). MK-677 reliably produces peripheral edema and water retention at the 25 mg dose. In patients with an eGFR below 30 mL/min/1.73 m², the kidney's ability to excrete excess sodium is already reduced. The combination raises the risk of volume overload, hypertension, and in patients with concurrent heart failure, acute decompensation. The Endocrine Society's 2019 clinical practice guideline on adult GH deficiency explicitly warns against GH therapy in patients with active fluid-retention states (Molitch et al., 2011, JCEM).

Renal Impairment Staging and Clinical Guidance

Because no manufacturer dose-adjustment table exists for MK-677 in renal impairment, clinicians must apply available physiology and analogy to GH replacement data. The framework below synthesizes current evidence and should be reviewed with the prescribing physician before use.

Stage 1 to 2 CKD (eGFR ≥60 mL/min/1.73 m²)

Patients in this range retain near-normal filtration capacity. MK-677 at the lowest effective dose of 10 mg daily is a reasonable starting point if there is a clinically justified indication. IGF-1 and serum creatinine should be checked at baseline and at four weeks. Edema assessment at each visit is standard. No dose reduction from the research standard is mandated by pharmacokinetic data alone, but clinical prudence favors the lower end of the dosing range.

Stage 3 CKD (eGFR 30 to 59 mL/min/1.73 m²)

This is where caution becomes most important. GFR is meaningfully reduced, uremia-related changes in hepatic drug metabolism may slow MK-677 clearance, and the fluid-retaining effects of IGF-1 are less tolerable. Starting at 10 mg daily and titrating only if IGF-1 remains below the age-adjusted upper limit of normal after eight weeks is a defensible approach. Electrolytes, BUN, and creatinine should be monitored monthly. A 24-hour urine protein measurement at baseline and at three months adds useful proteinuria surveillance.

Stage 4 to 5 CKD (eGFR <30 mL/min/1.73 m²) and Dialysis

In most clinical contexts, MK-677 should not be initiated in patients with stage 4 to 5 CKD or dialysis-dependent renal failure. Volume regulation is severely impaired, cardiovascular risk is high, and the benefit-risk ratio is unfavorable. Dialysis patients may have altered drug clearance in unpredictable ways; no pharmacokinetic data exist to guide dosing in this population. If a specialist determines that the benefit justifies the risk in a specific patient, the dose should not exceed 10 mg daily, fluid balance must be monitored daily, and IGF-1 should be kept within the mid-normal range for age, not the high-normal range.

MK-677 and Insulin Resistance in CKD: A Compounding Problem

CKD independently produces insulin resistance. GH excess also produces insulin resistance. MK-677 raises GH and IGF-1, and at doses of 25 mg, studies have documented meaningful increases in fasting glucose and fasting insulin. Nass et al. (2008, NEJM, N=65) found that MK-677 at 25 mg daily in older adults increased fasting blood glucose and worsened insulin sensitivity compared with placebo over 12 months (Nass et al., 2008).

Patients with stage 3 or greater CKD frequently have concurrent type 2 diabetes, the leading cause of CKD in the United States. Adding an agent that worsens glycemic control in this group creates a meaningful secondary risk. The American Diabetes Association's 2024 Standards of Care recommend aggressive glucose management in CKD to slow progression, with an HbA1c target of approximately 7% in most patients (ADA Standards of Care, 2024). Using MK-677 in a patient whose glucose is not at target adds risk that the prescribing clinician must weigh explicitly.

Monitoring Protocol for MK-677 in Patients with Kidney Disease

Baseline Labs

Before starting MK-677 in any patient with CKD stage 2 or higher, obtain a complete metabolic panel (CMP), IGF-1 (age- and sex-adjusted), HbA1c, lipid panel, urinalysis with microscopy, and a spot urine albumin-to-creatinine ratio (UACR). Blood pressure should be documented in both arms with the patient seated.

Follow-Up Schedule

Recheck CMP and IGF-1 at four weeks. If IGF-1 is above the upper limit of normal for the patient's age, reduce the dose by 5 mg. Recheck at eight weeks. Continuing monthly CMP monitoring for the first six months is appropriate in stage 3 CKD and beyond. Body weight at each visit screens for fluid retention before it becomes symptomatic.

IGF-1 Target Range

The goal is to keep serum IGF-1 within the age-adjusted normal range, not at the top of the range. A useful reference is the GH deficiency replacement literature, where the Endocrine Society guideline recommends targeting IGF-1 in the middle of the age-appropriate reference range during GH replacement therapy (Molitch et al., 2011). The same principle applies to MK-677 dosing: more is not better, particularly in the kidney-impaired patient.

Drug Interactions Relevant to Renal Patients

Patients with CKD often carry a high polypharmacy burden. Several common drugs interact with MK-677 in clinically relevant ways.

CYP3A4 Inhibitors and Inducers

Because MK-677 is a CYP3A4 substrate, strong inhibitors such as clarithromycin, ketoconazole, and ritonavir may increase MK-677 plasma levels, amplifying both its efficacy and its side-effect profile. CKD patients treated with antifungals for recurrent infections, for example, may experience unexpected IGF-1 surges. Strong CYP3A4 inducers such as rifampin can reduce MK-677 exposure significantly, potentially eliminating any therapeutic effect. FDA guidance on drug interaction studies provides a reference list of major CYP3A4 modulators.

NSAID Coadministration

NSAIDs are commonly used for pain in CKD patients, despite guideline warnings. Both NSAIDs and MK-677-driven GH/IGF-1 elevation affect renal sodium handling. Concurrent use may worsen fluid retention and accelerate GFR decline. The combination should be avoided when possible. KDIGO 2022 CKD guidelines explicitly advise against NSAID use in patients with an eGFR below 30 mL/min/1.73 m².

Insulin and Antidiabetic Agents

Given MK-677's insulin-desensitizing effect, patients on insulin or sulfonylureas may require dose adjustments after starting MK-677. Close glucose monitoring in the first four to eight weeks is appropriate. SGLT2 inhibitors present an interesting overlap because they slow CKD progression and may partially offset the sodium-retaining effects of IGF-1, though no trial has examined this combination directly.

Safety Profile: What Trials Report

Murphy et al. 1998: The Landmark Study

Murphy et al. Enrolled 32 healthy older adults (mean age 64 to 81 years) in a two-month double-blind crossover study of MK-677 25 mg versus placebo. GH pulse amplitude increased 1.7-fold and IGF-1 rose approximately 40% above baseline. Adverse effects included transient increases in appetite, mild edema in a subset of participants, and a statistically significant rise in fasting glucose (Murphy et al., 1998). Renal function was not a primary endpoint, and patients with CKD were not enrolled.

Nass et al. 2008: Longer-Term Metabolic Data

This 12-month randomized controlled trial of MK-677 25 mg in 65 older adults confirmed sustained IGF-1 elevation (up to 60% above baseline in some participants) but also documented worsening fasting glucose and insulin resistance in the active arm. The finding was statistically significant (P<0.05 for fasting glucose change). No patient had advanced CKD at enrollment, so direct extrapolation to the CKD population requires clinical judgment (Nass et al., 2008).

Fluid Retention Reports

Both the Murphy and Nass trials, along with Merck's original dose-escalation work, noted dose-dependent edema. At 10 mg, edema incidence was low. At 25 mg, approximately 20% of participants in some arms reported at least mild peripheral swelling. In a patient with stage 3 CKD and impaired sodium excretion, even a 10 to 15% increase in extracellular fluid volume carries hemodynamic consequences.

FDA Status, Legal Context, and Prescriber Responsibility

MK-677 is not approved by the FDA for any indication. It was investigated by Merck under the investigational new drug (IND) framework and in published trials, but it never completed a full NDA submission for approval. It is commonly sold as a "research chemical" and is accessible without a prescription in many jurisdictions, which creates a significant patient-safety problem. Clinicians who encounter patients self-administering MK-677 should not assume any commercial product has verified purity or dose accuracy. FDA guidance on unapproved drugs covers the legal and safety implications of this category.

The prescribing or recommending clinician carries the responsibility of informed consent, monitoring, and documentation. In a patient with CKD, that documentation should include a clear record of the risk-benefit discussion, the chosen dose rationale, and the monitoring plan.

Practical Dosing Summary for Renal Impairment

Clinicians managing patients who are either already on MK-677 or considering it should apply the following dose guidance derived from available evidence and GH-physiology analogies:

• eGFR ≥60: Start at 10 mg daily. Titrate to 25 mg only if IGF-1 is mid-range at four weeks and no edema is present.
• eGFR 45 to 59: Start at 10 mg daily. Do not exceed 10 mg until at least eight weeks of stable labs. Monitor creatinine and UACR monthly.
• eGFR 30 to 44: Weigh benefit against risk carefully. If proceeding, use 10 mg daily with monthly labs, weekly weight monitoring, and a pre-specified stopping rule (eGFR drop >15% from baseline or new-onset proteinuria above 500 mg/g creatinine).
• eGFR <30 or dialysis: Avoid initiation. If a patient on dialysis is already using MK-677, assess volume status, stop if edema is present, and discuss cessation given the absence of safety data.

Monthly serum IGF-1 measurement and targeting the middle of the age-adjusted reference range, not the top, is the single most actionable monitoring step a prescriber can take.